Details

Autor(en) / Beteiligte

• Weis, Sebastian
• Scherag, André
• Baier, Michael
• Kiehntopf, Michael
• Kamradt, Thomas
• Kolanos, Steffi
• Ankert, Juliane
• Glöckner, Stefan
• Makarewicz, Oliwia
• Hagel, Stefan
• Bahrs, Christina
• Kimmig, Aurelia
• Proquitté, Hans
• Guerra, Joel
• Rimek, Dagmar
• Löffler, Bettina
• Pletz, Mathias W.
• Hotz, Thomas
• Local Cooperation Partners
• Enders, Petra
• Koch, Renate
• Mai, Steffen
• Ullrich, Matthias
• Richert, Cora
• Eibner, Cornelius
• Meinung, Bettina
• Stötzer, Kay
• Köhler, Julia
• Cipowicz, Hans
• Pinkwart, Christine
• Bauer, Michael
• Dickmann, Petra
• Licht, Annika
• Scholz, Juliane
• Wetzker, Wibke
• Hartung, Anita
• Weiss, Daniel
• Thieme, Lara
• Hanf, Gabi
• Schnizer, Clara
• Müller, Jasmin
• Kosenkow, Jennifer
• Röstel, Franziska
• Andreas, Nico
• Marquardt, Raphaela
• Deinhardt-Emmer, Stefanie
• Kuhn, Sebastian

Titel

Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study

Ist Teil von

• Clinical microbiology and infection, 2021-03, Vol.27 (3), p.470.e1-470.e9

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Due to a substantial proportion of asymptomatic and mild courses, many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed to determine and characterize the rate of SARS-CoV-2 infections and the resulting seroprevalence in a defined population. The primary objective of the study was to assess SARS-CoV-2 antibody seroprevalence using six different IgG-detecting immunoassays. Secondary objectives of the study were: (a) to determine potential risk factors for symptomatic versus asymptomatic coronavirus disease 2019 courses, and (b) to investigate the rate of virus RNA-persistence. CoNAN is a population-based cohort study performed in the community Neustadt am Rennsteig, Germany, which was quarantined from 22 March to 5 April after six SARS-CoV-2 cases were detected in the village's population. The SARS-CoV-2 outbreak comprised 51 cases and 3 deaths. The CoNAN study was performed from 13 May to 22 May 2020, 6 weeks after a SARS-CoV-2 outbreak. We enrolled a total of 626 participants (71% of the community population) for PCR and antibody testing in the study. All actual SARS-CoV-2 PCR tests were negative. Fifty-two out of 620 (8.4%) participants had antibodies against SARS-CoV-2 in at least two different assays. There were 38 participants with previously PCR-confirmed SARS-CoV-2 infection. Of those, only 19 (50%) displayed anti-SARS-CoV-2 antibodies. We also show that antibody-positive participants with symptoms compatible with a respiratory tract infection had significantly higher antibody levels then asymptomatic participants (EU-assay: median 2.9 versus 7.2 IgG-index, p 0.002; DS-assay: median 45.2 versus 143 AU/mL, p 0.002). Persisting viral replication was not detected. Our data question the relevance and reliability of IgG antibody testing to detect past SARS-CoV-2 infections 6 weeks after an outbreak. We conclude that assessing immunity for SARS-CoV-2 infection should not rely on antibody tests alone.